Hims & Hers (HIMS 6.81%) stock investors desperately need some positive news following the stock price crash in late June.*Stock prices used were the afternoon prices of June 26, 2025. The video was published on June 28, 2025. ...

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in stock price following the termination of its partnership with Novo Nordisk [1][3]. Group 1: Lawsuit Details - The class action lawsuit, Sookdeo v. Hims & Hers Health, Inc., involves allegations that Hims & Hers and its executives violated the Securities Exchange Act of 1934 [1]. - The lawsuit claims that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy, which jeopardized patient safety [2]. - Following the announcement of the termination of the partnership with Novo Nordisk on June 23, 2025, Hims & Hers' stock price fell by more than 34% [3]. Group 2: Legal Process - Investors who purchased Hims & Hers securities during the class period (April 29, 2025, to June 23, 2025) can seek appointment as lead plaintiff in the class action lawsuit [4]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [4]. Group 3: Company Background - Hims & Hers is a telehealth company that provides prescription medications, over-the-counter medications, and personal care products [2]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its success in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [5].

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Hims & Hers Health, Inc. regarding potential securities fraud or unlawful business practices [1] - Novo Nordisk has discontinued its partnership with Hims & Hers due to non-compliance with legal regulations concerning the sale of compounded drugs, which has raised patient safety concerns [3] - Following the announcement of the partnership termination, Hims & Hers' stock price dropped by $22.24, or 34.63%, closing at $41.98 per share [3] Company Overview - Hims & Hers Health, Inc. is publicly traded on the NYSE under the ticker symbol HIMS [1] - The company has faced scrutiny regarding its business practices, particularly in relation to the sale of compounded drugs [3] Legal and Regulatory Context - The investigation by Pomerantz LLP suggests potential legal challenges for Hims & Hers, which may impact investor confidence [1] - Novo Nordisk's decision to end the partnership highlights regulatory compliance issues that could affect Hims & Hers' operations and reputation [3]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Hims & Hers Health, Inc. due to allegations of misleading statements and the termination of its partnership with Novo Nordisk, which has significantly impacted the company's stock price [3][5][6]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $50,000 in Hims between April 29, 2025, and June 23, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Hims, with a deadline of August 25, 2025, for investors to seek the role of lead plaintiff [3][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Hims - The complaint alleges that Hims and its executives violated federal securities laws by making false or misleading statements regarding the safety and legitimacy of their products [5]. - Specific allegations include the deceptive promotion of illegitimate versions of Wegovy® and the risk of termination of collaboration with Novo Nordisk due to these practices [5][6]. - Following the announcement of the partnership termination by Novo Nordisk, Hims' stock price fell by $22.24, or 34.6%, closing at $41.98 per share on June 23, 2025 [6]. Group 3: Call for Information - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Hims' conduct [8].

Core Insights - The article discusses investor inquiries regarding a growth stock that has experienced a significant price decline [1] Group 1 - The stock prices referenced were from the afternoon of June 25, 2025 [1] - The video related to this stock was published on June 27, 2025 [1]

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. - Two complaints have been filed, with the first case captioned Sookdeo v. Hims & Hers Health, Inc., and a subsequent similar complaint captioned Yaghsizian v. Hims & Hers Health, Inc. [2]. Group 2: Allegations Against Hims & Hers - Hims & Hers operates a telehealth platform providing access to healthcare consultations and wellness products, and recently announced a collaboration with Novo Nordisk to sell the weight loss drug Wegovy [3]. - Allegations include misrepresentation of the partnership with Novo Nordisk, claiming that Hims & Hers could offer both Wegovy and compounded semaglutide, and asserting compliance with FDA regulations [4]. Group 3: Stock Market Reaction - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' alleged deceptive practices, the stock price fell by $22.24 per share, a decline of over 34%, from $64.22 on June 20, 2025, to $41.98 on June 23, 2025 [5].

Hims & Hers (HIMS 6.81%) is attracting investors looking to buy the dip in this impressive growth stock.*Stock prices used were the afternoon prices of June 24, 2025. The video was published on June 26, 2025. ...

Core Viewpoint - Hims & Hers Health, Inc. is facing securities class action lawsuits due to allegations of failing to disclose material information during the class period, which has led to a significant drop in share price following a partnership termination announcement by Novo Nordisk [3][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to file lead plaintiff applications in the securities class action lawsuits against Hims, specifically for those who purchased securities between April 29, 2025, and June 23, 2025 [1]. - The lawsuits are pending in the United States District Court for the Northern District of California, with the first case being Sookdeo v. Hims & Hers Health, Inc. and a subsequent case expanding the class period [5]. Group 2: Company Impact - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims, citing violations of laws regarding the sale of compounded drugs and concerns over patient safety due to potentially unsafe ingredients in products sold by Hims [4]. - Following this announcement, Hims' share price fell by $22.24, or 34.6%, closing at $41.98 per share on unusually heavy trading volume [4].

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for alleged violations of federal securities laws during the Class Period from April 29, 2025, to June 23, 2025 [1][2]. Group 1: Allegations Against Hims & Hers - The lawsuit claims that Hims & Hers made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3]. - Specific allegations include the deceptive promotion of illegitimate versions of Wegovy® that jeopardized patient safety, risking the termination of its collaboration with Novo Nordisk [3]. - The complaint also states that positive statements made by the company regarding its business prospects were misleading and lacked a reasonable basis [3]. Group 2: Details of Misleading Statements - Allegations include that Hims & Hers misrepresented its communication with Novo Nordisk, suggesting it would ensure continued access to Wegovy for subscribers [4]. - The complaint asserts that Novo approved Hims' offerings of compounded semaglutide products, which were falsely presented as compliant with regulations [4]. - Additionally, it is claimed that Hims & Hers made positive statements about the partnership with Novo and the availability of Wegovy alongside compounded products, which were misleading [4]. Group 3: Next Steps for Investors - Investors who suffered losses in Hims & Hers have until August 25, 2025, to request to be appointed as lead plaintiff in the class action [5]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [6].

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. concerning allegations of securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves claims that Hims & Hers and certain officers/directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Hims & Hers securities during the Class Period have until August 25, 2025, to request to be appointed as Lead Plaintiff [3]. Group 2: Partnership and Stock Impact - On April 29, 2025, Hims & Hers announced a collaboration with Novo Nordisk to sell a bundled offering of Wegovy® [3]. - On June 23, 2025, Novo Nordisk terminated its partnership with Hims & Hers, citing deceptive promotion and selling of illegitimate versions of Wegovy® that jeopardized patient safety [3]. - Following the termination announcement, Hims & Hers' stock price dropped by $22.24, or 34.63%, closing at $41.98 per share [3].